The Gap Between Your Pharmacist's Prescription Pad and Your Actual Needs

There's a headline that should alarm anyone who lives with a chronic health condition in Canada: in 2024, the median wait time between a GP referral and specialist treatment reached 30 weeks. That is not a typo. Thirty weeks — and it is the longest ever recorded. For context, that same wait was 9.3 weeks in 1993. We have more than tripled it in three decades.

In British Columbia specifically, the median total wait sits at 29.5 weeks. That's nearly seven months between your family doctor deciding you need specialist care and you actually receiving it.

I want to talk about what happens to a body — and a nervous system — during those seven months. And I want to talk about a well-intentioned policy change that is quietly being confused for a solution to a problem it wasn't designed to fix.

The MACS Program: What It Is, and What It Isn't

Since June 2023, BC pharmacists have had the authority to diagnose and prescribe for 21 minor ailments — things like uncomplicated UTIs, cold sores, pink eye, mild acne, and tension-type headaches. This is called the Minor Ailments and Contraception Service, or MACS, and it is genuinely useful. Over 640,000 British Columbians have been seen under this program since its launch. For people who can't get a timely appointment with their family doctor, being able to walk into a pharmacy and get a prescription for an antibiotic for a UTI, or an antiviral for a cold sore, is meaningful access.

But let's be clear about the edges of this program, because I think they matter.

When it comes to pain, BC pharmacists can prescribe NSAIDs — prescription-strength ibuprofen or naproxen — for musculoskeletal pain. That's the boundary. Non-NSAID pain medications, including tramadol, colchicine, and anything in the opioid class, are outside of scope. Triptans for migraine are off the table. Neuropathic pain agents aren't covered. And for antibiotics, the only qualifying condition is an uncomplicated UTI. Anything beyond that — a more complex infection, a condition requiring a targeted antibiotic — requires a physician or nurse practitioner.

This is not a criticism of MACS. The program is doing what it was designed to do. The problem is that people living with chronic illness, chronic pain, and complex conditions sit almost entirely outside its reach — and those are exactly the people for whom the system's gaps are most consequential.

What the Wait Actually Does to Your Body

Here is what concerns me most as a clinician who works in chronic pain and chronic illness: the research on what happens to the nervous system during untreated or undertreated pain is unambiguous and deeply under-communicated to patients.

Acute pain, when it is not effectively managed, doesn't simply sit still and wait for treatment. It changes the nervous system. A 2024 review published in Neurotransmitter found that neuroplasticity — the nervous system's capacity for adaptive change — plays a central role in the transition from acute to chronic pain. During this process, neurons become progressively sensitized to pain stimuli, synaptic connections are altered, and what began as a localized response can become embedded in the central nervous system itself.

This process has a name: central sensitization. Research published in Frontiers in Molecular Neuroscience describes it as a multidimensional and active pathophysiological process — not a passive consequence of time passing, but a structural and functional reorganization of the nervous system driven by persistent nociceptive input. Once that reorganization takes hold, the pain no longer requires the original trigger to fire. It has, in a very literal neurological sense, become its own condition.

Put plainly: untreated pain teaches the nervous system to be better at producing pain. And the longer that teaching goes on, the harder it becomes to interrupt.

A 2022 review in The Egyptian Journal of Neurology, Psychiatry and Neurosurgery reinforced this, identifying maladaptive neuroplasticity and central sensitization as major components of a wide range of chronic pain conditions — and as meaningful targets for early intervention, precisely because early intervention is when the window is still open.

This is why delayed access to appropriate medication management isn't just an inconvenience. It is a risk factor for chronification. And chronification changes the entire clinical picture — the treatment complexity, the duration of care, the patient's quality of life, and the cost to the healthcare system.

Seven Months Is Long Enough to Change a Nervous System

Statistics Canada's 2024 survey on health care access found that among Canadians who waited for specialist care, 64% reported their lives were affected by the wait. Of those, two-thirds experienced worry, anxiety, and stress; over a third reported pain; nearly a third reported difficulties with activities of daily living; and 22% said their health had deteriorated while they waited.

Those are not minor inconveniences. That is a measurable, documented worsening of condition during the wait itself.

A Fraser Institute analysis on the effects of wait times in Canada put it in starker terms: the advance of disease during a delay can mean longer, more complex, and more intensive treatments than were required when the problem was first identified. In some cases, the wait transforms a potentially reversible condition into a chronic or irreversible one. Waiting for health care, the analysis noted, can also contribute to chronic addiction to painkillers and narcotics — an outcome that carries its own devastating downstream consequences.

Canada's wait times have increased 195% since 1993, according to 2023 figures cited in a PMC review on healthcare wait time challenges. A 2024 Canadian Medical Journal report on wait time challenges identified this as a significant public health concern, noting that longer waits are directly linked to deteriorated health outcomes, higher treatment costs, increased burden while living with disability, and loss of income.

The People Falling Through the Gap

The patients most harmed by these delays are not the ones with straightforward, acute presentations. They are the ones with complex, multisystem, or poorly understood conditions — the patients for whom the 21 minor ailments list offers almost nothing. People with fibromyalgia, ME/CFS, autoimmune disease, chronic neuropathic pain, complex regional pain syndrome, headache disorders. People waiting months for pain specialist referrals while their nervous systems reorganize around undertreated pain. People who cannot get a timely prescription renewal and are managing complicated medication regimens without adequate prescriber support.

These are also, disproportionately, women — who are 66% more likely to be misdiagnosed than men in the first place, and who wait longer for pain to be taken seriously. They are people in rural and remote communities where pharmacist prescribing may be the only accessible healthcare for weeks at a time, and where the limits of that pharmacist's prescribing authority hit differently than they do in urban centres with walk-in clinics on every block.

What Broader Scope Could Actually Do

I want to be careful here not to suggest that pharmacists prescribing opioids or complex pain medications is the straightforward answer — it isn't, and the risks associated with unsupervised initiation of those medications are real. But the gap between what pharmacists are currently permitted to do and what chronically ill patients actually need is not a gap that exists for good clinical reasons in every case.

Other Canadian provinces have more expansive prescribing authorities in certain contexts. Alberta, for example, has among the broadest pharmacist scopes of practice in the country. There are models across health systems internationally where pharmacist-led collaborative care for chronic conditions — including pain management — has reduced wait times, improved medication adherence, and produced better patient outcomes without increasing harm.

The MACS program is a meaningful start, and the pharmacists implementing it are doing genuinely important work. But start should not be confused with finish.

What I Want Patients to Know

If you are living with a chronic condition and you are waiting — for a referral, for a specialist appointment, for a prescription, for someone in the system to take your symptoms seriously — please know that this is a structural problem, not a personal failing. The system is not keeping pace with the need, and people are being harmed by delays that are measurable, documented, and preventable.

If your pain is undertreated while you wait, that is not a reason to feel shame or to push through without advocating for yourself. The research is clear that undertreated pain changes the nervous system over time, and you have every right to push back, ask questions, explore bridging options, and demand timely access to care.

The pharmacist at your local pharmacy can do more than they could two years ago. That is worth knowing and worth using. But they are working within a framework that was built for uncomplicated, acute presentations — and many of us are not that.

Better access to medication management for people with chronic illness is not a luxury ask. Given what we know about how the nervous system responds to untreated pain, it is a question of whether we prevent chronification or we pay to treat it after the window has already closed.

The evidence tells us which option costs less — in every sense of that word.

Elysia Bronson is a Registered Clinical Counsellor and founder of The Woods Counselling Co. in Abbotsford, BC, specializing in chronic illness, chronic pain, and trauma. She serves as Interprofessional Co-Chair of the Canadian Pain Society and has published in the Canadian Journal of Pain. She practices online across Canada.